COVID-19 future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 8: | Line 8: | ||
==Future or Investigational Therapies== | ==Future or Investigational Therapies== | ||
=== Immune Targets === | === Anti-virals === | ||
* Chloroquine | |||
* Arbidol | |||
* Remdesivir | |||
* Favipiravir | |||
=== Vaccine === | |||
==== Immune Targets ==== | |||
* The B cell and T cell epitopes derived from the spike (S) and nucleocapsid (N) proteins are currently under investigation as immune targets for development of vaccine. | * The B cell and T cell epitopes derived from the spike (S) and nucleocapsid (N) proteins are currently under investigation as immune targets for development of vaccine. | ||
* Phylogenetic similarity between SARS-CoV and COVID-19 at the level of structural proteins S, E, M, and N is providing guidance for development of a possible vaccine. | * Phylogenetic similarity between SARS-CoV and COVID-19 at the level of structural proteins S, E, M, and N is providing guidance for development of a possible vaccine. | ||
=== Current Clinical Trials === | ==== Current Clinical Trials ==== | ||
The following countries are currently working on the development of a vaccine for COVID-19 (SARS-CoV2) | The following countries are currently working on the development of a vaccine for COVID-19 (SARS-CoV2) | ||
| Line 35: | Line 44: | ||
* Following successful in vitro experiments, animal testing has begun in University of Queensland in Australia | * Following successful in vitro experiments, animal testing has begun in University of Queensland in Australia | ||
=== Prior Work === | ==== Prior Work ==== | ||
The following table depicts major vaccine products that have been developed against SARS-CoV and MERS-CoV: | The following table depicts major vaccine products that have been developed against SARS-CoV and MERS-CoV: | ||
<br /> | <br /> | ||
Revision as of 18:01, 19 March 2020
|
COVID-19 Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
COVID-19 future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of COVID-19 future or investigational therapies |
|
Risk calculators and risk factors for COVID-19 future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Future or Investigational Therapies
Anti-virals
- Chloroquine
- Arbidol
- Remdesivir
- Favipiravir
Vaccine
Immune Targets
- The B cell and T cell epitopes derived from the spike (S) and nucleocapsid (N) proteins are currently under investigation as immune targets for development of vaccine.
- Phylogenetic similarity between SARS-CoV and COVID-19 at the level of structural proteins S, E, M, and N is providing guidance for development of a possible vaccine.
Current Clinical Trials
The following countries are currently working on the development of a vaccine for COVID-19 (SARS-CoV2)
USA
- Beth Israel Deaconess Medical Center (BIDMC), Boston and Johnson & Johnson (J&J) are currently collaborating to advance COVID-19 vaccine. A Phase I trial is expected to launch during the last quarter of 2020. AdVac and PER.C6 technologies are being used for rapid production.
- National Institute for Allergy and Infectious Diseases (NIAID) has announced that a phase 1 trial has begun for COVID-19 immunization in Washington state.
- The trial includes 45 young, healthy volunteers with different doses of immunization shots co-developed by NIH and Moderna Inc.
Israel
- Researchers at Israel’s Institute for Biological Research are expected to announce in the coming days that they have completed development of a vaccine for COVID-19
China
- China was the first country to release the genetic sequence of the virus on open scientific databases so that research institutes and commercial companies could try to develop treatments and vaccines without needing to obtain samples.
- China has announced the first animal tests.
Australia
- Following successful in vitro experiments, animal testing has begun in University of Queensland in Australia
Prior Work
The following table depicts major vaccine products that have been developed against SARS-CoV and MERS-CoV:
| Vaccine Base | Antigen | Clinical Testing | Pros | Cons |
|---|---|---|---|---|
| DNA |
|
Phase I, II
(NCT03721718) |
|
|
| Viral Vector |
|
Phase I
(NCT03399578, NCT03615911) |
|
|
| Conjugated subunit |
|
|
| |
| Virion |
|
|
| |
| Inactivated |
|
|
| |
| Live attenuated |
|
|